nach oben

Irish Journal of Medical Science (1971 -)

Erschienen in:

19.08.2016 | Original Article

The association between MMP2 −1306 C > T (rs243865) polymorphism and risk of prostate cancer

verfasst von: L. Shajarehpoor Salavati, F. Tafvizi, H. K. Manjili

Erschienen in: Irish Journal of Medical Science (1971 -) | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Abstract

Background

Prostate cancer is the second most common cancer in men. Matrix metalloproteinase-2 (MMP2) is the most important member of the matrix metalloproteinase family. MMP2 digests the basement membrane and causes changes in the extracellular matrix which in turn facilitate cancer invasion. It, therefore, has a major role in tumor angiogenesis. Previous studies have identified a single-nucleotide polymorphism C/T at position −1306 of MMP2 gene promoter which is a key regulatory factor in cancer progression.

Aim

The present study aimed to determine the association between MMP2 polymorphism and the risk of prostate cancer in Iranian men.

Methods

This case–control study was performed on 50 paraffin-embedded prostate cancer tissue samples and 54 blood samples from healthy men. Genotyping of the samples was performed using high-resolution melting analysis (HRM). Finally, 20 % of the genotypes were confirmed by sequencing.

Results

No significant associations were found between CT and TT genotypes and the risk of prostate cancer. However, there were no significant relationships between the genotypes and the studied factors, e.g., age, pathological stage, and Gleason Score.

Conclusion

MMP2 −1306 C > T (rs243865) polymorphism was not significantly related with prostate cancer susceptibility in Iranian men.

Jemal A, Siegel R, Ward E et al (2009) Cancer statistics. CA Cancer J Clin 59:225–249CrossRefPubMed

Carter BS, Carter HB, Isaacs JT (1990) Epidemiologic evidence regarding predisposing factors to prostate cancer. Prostate 16:187–197CrossRefPubMed

Bishop JL, Davies A, Ketola K et al (2015) Regulation of tumor cell plasticity by the androgen receptor in prostate cancer. Endoc Relat Cancer 22:165–182CrossRef

Bookstein R, MacGrogan D, Hilsenbeck SG et al (1993) p53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res 53:3369–3373PubMed

Björndahl M, Cao R, Nissen LJ et al (2005) Insulin-like growth factors 1 and 2 induce lymphangiogenesis in vivo. Proc Natl Acad Sci USA 102:15593–15598CrossRefPubMedPubMedCentral

Hojilla CV, Mohammed FF, Khokha R (2003) Matrix metalloproteinases and their tissue inhibitors direct cell fate during cancer development. Br J Cancer 89:1817–1821CrossRefPubMedPubMedCentral

Forget MA, Desrosiers RR, Béliveau R (1999) Physiological roles of matrix metalloproteinases: implications for tumor growth and metastasis. Can J Physiol Pharmacol 77:465–480CrossRefPubMed

Chambers AF, Matrisian LM (1997) Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 89:1260–1270CrossRefPubMed

Egeblad M, Werb Z (2002) New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2:161–174CrossRefPubMed

10.

Delgado-Enciso I, Cepeda-Lopez FR, Monrroy-Guizar EA et al (2008) Matrix metalloproteinase-2 promoter polymorphism is associated with breast cancer in a Mexican population. Gynecol Obstet Invest 65:68–72CrossRefPubMed

11.

Ozalp S, Tanir HM, Yalcin OT et al (2003) Prognostic value of matrix metalloproteinase-9 (gelatinase-B) expression in epithelial ovarian tumors. Eur J Gynaecol Oncol 24:417–420PubMed

12.

Price SJ, Greaves DR, Watkins H (2001) Identification of novel, functional genetic variants in the human matrix metalloproteinase-2 gene: role of Sp1 in allele-specific transcriptional regulation. J Biol Chem 276:7549–7558CrossRefPubMed

13.

Ogawa K, Chen F, Kuang C et al (2004) Suppression of matrix metalloproteinase-9 transcription by transforming growth factor-beta is mediated by a nuclear factor-kappaB site. Biochem J 381:413–422CrossRefPubMedPubMedCentral

14.

Yu C, Zhou Y, Miao X et al (2004) Functional haplotypes in the promoter of matrix metalloproteinase-2 predict risk of the occurrence and metastasis of esophageal cancer. Cancer Res 64:7622–7628CrossRefPubMed

15.

Chan PK, Chan DP, To KF et al (2001) Evaluation of extraction methods from paraffin wax embedded tissues for PCR amplification of human and viral DNA. J Clin Pathol 54:401–403CrossRefPubMedPubMedCentral

16.

Pharoah PD, Dunning AM, Ponder BA et al (2004) Association studies for finding cancer-susceptibility genetic variants. Nat Rev Cancer 4:850–860CrossRefPubMed

17.

Lichtenstein P, Holm NV, Verkasalo PK et al (2000) Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 343:78–85CrossRefPubMed

18.

Yoon SO, Park SJ, Yun CH et al (2003) Roles of matrix metalloproteinases in tumor metastasis and angiogenesis. J Biochem Mol Biol 36:128–137PubMed

19.

Curran S, Murray GI (1999) Matrix metalloproteinases in tumor invasion and metastasis. J Pathol 189:300–308CrossRefPubMed

20.

Stamenkovic I (2000) Matrix metalloproteinases in tumor invasion and metastasis. Semin Cancer Biol 10:415–433CrossRefPubMed

21.

Sternlicht MD, Werb Z (1999) In: Kreis T, Vale R (eds) Guidebook to the extracellular matrix and adhesion proteins. Oxford University Press, Oxford, UK, pp 503–562

22.

Ye S (2000) Polymorphism in matrix metalloproteinase gene promoters: implication in regulation of gene expression and susceptibility of various diseases. Matrix Biol 19:623–629CrossRefPubMed

23.

Bian J, Sun Y (1997) Transcriptional activation by p53 of the human type IV collagenase (gelatinase A or matrix metalloproteinase 2) promoter. Mol Cell Biol 17:6330–6338CrossRefPubMedPubMedCentral

24.

Qin H, Sun Y, Benveniste EN (1999) The transcription factors Sp1, Sp3, and AP-2 are required for constitutive matrix metalloproteinase-2 gene expression in astroglioma cells. J Biol Chem 274:29130–29137CrossRefPubMed

25.

Jacobs EJ, Hsing AW, Bain EB et al (2008) Polymorphisms in angiogenesis-related genes and prostate cancer. Cancer Epidemiol Biomarkers Prev 17:972–977CrossRefPubMed

26.

Haque S, Akhter N, Lohani M et al (2015) Matrix Metalloproteinase-2−1306 C > T Gene Polymorphism is Associated with Reduced Risk of Cancer: a Meta-analysis. Asian Pac J Cancer Prev 16:889–896CrossRefPubMed

27.

Liu D, Guo H, Li Y et al (2012) Association between polymorphisms in the promoter regions of matrix metalloproteinases (MMPs) and risk of cancer metastasis: a meta-analysis. PLoS One 7:e31251CrossRefPubMedPubMedCentral

28.

Peng B, Cao L, Ma X et al (2010) Meta-analysis of association between matrix metalloproteinases 2, 7 and 9 promoter polymorphisms and cancer risk. Mutagenesis 25:371–379CrossRefPubMed

29.

Yaykaşli KO, Kayikçi MA, Yamak N et al (2014) Polymorphisms in MMP-2 and TIMP-2 in Turkish patients with prostate cancer. Turk J Med Sci 44:839–843CrossRefPubMed

30.

Elander N, Söderkvist P, Fransén K (2006) Matrix metalloproteinase (MMP) -1, -2, -3 and -9 promoter polymorphisms in colorectal cancer. Anticancer Res 26:791–795PubMed

31.

McColgan P, Sharma P (2009) Polymorphisms of matrix metalloproteinases 1, 2, 3 and 9 and susceptibility to lung, breast and colorectal cancer in over 30,000 subjects. Int J Cancer 125:1473–1478CrossRefPubMed

32.

Kader AK, Shao L, Dinney CP et al (2006) Matrix metalloproteinase polymorphisms and bladder cancer risk. Cancer Res 66:11644–11648CrossRefPubMed

33.

Xu E, Lai M, Lv B et al (2004) A single nucleotide polymorphism in the matrix metalloproteinase-2 promoter is associated with colorectal cancer. Biochem Biophys Res. Commun 324:999–1003CrossRefPubMed

34.

Yu C, Pan K, Xing D et al (2002) Correlation between a single nucleotide polymorphism in the matrix metalloproteinase-2 promoter and risk of lung cancer. Cancer Res 62:6430–6433PubMed

35.

Miao X, Yu C, Tan W et al (2003) A functional polymorphism in the matrix metalloproteinase-2 gene promoter (−1306C/T) is associated with risk of development but not metastasis of gastric cardia adenocarcinomal. Cancer Res 63:3987–3990PubMed

36.

Zhou Y, Yu C, Miao X et al (2004) Substantial reduction in risk of breast cancer associated with genetic polymorphisms in the promoters of the matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 genes. Carcinogenesis 25:399–404CrossRefPubMed

37.

Grieu F, Li WQ, Iacopetta B (2004) Genetic polymorphisms in the MMP-2 and MMP-9 genes and breast cancer phenotype. Breast Cancer Res Treat 88:197–204CrossRefPubMed

38.

Dos Reis ST, Villanova FE, De Andrade PM (2008) Polymorphisms of the matrix metalloproteinases associated with prostate cancer. Mol Med Rep 1:517–520PubMed

39.

Dos Reis ST, Villanova FE, Andrade PM (2010) Matrix metalloproteinase-2 polymorphism is associated with prognosis in prostate cancer. Urol Oncol 28:624–627CrossRefPubMed

40.

Srivastava P, Lone TA, Kapoor R et al (2012) Association of promoter polymorphisms in MMP2 and TIMP2 with prostate cancer susceptibility in north India. Arch Med Res 43:117–124CrossRefPubMed

Titel: The association between MMP2 −1306 C > T (rs243865) polymorphism and risk of prostate cancer
verfasst von: L. Shajarehpoor Salavati
F. Tafvizi
H. K. Manjili
Publikationsdatum: 19.08.2016
Verlag: Springer London
Erschienen in: Irish Journal of Medical Science (1971 -) / Ausgabe 1/2017
Print ISSN: 0021-1265
Elektronische ISSN: 1863-4362
DOI: https://doi.org/10.1007/s11845-016-1492-9

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

16.04.2024 | Chronische Herzinsuffizienz | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

The association between MMP2 −1306 C > T (rs243865) polymorphism and risk of prostate cancer

Abstract

Background

Aim

Methods

Results

Conclusion

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Sind Betablocker auch für ältere herzschwache Personen nützlich?

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

Manche Gestagene können das Risiko für Meningeome erhöhen

Stillende Frauen haben geringeres kardiovaskuläres Risiko

Update Innere Medizin

Springer Medizin

Abstract

Background

Aim

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2017

Prospective audit of a dedicated ear, nose and throat emergency department and 24-year comparison

EWTD compliance amongst Anaesthesia trainees in Ireland

Odontogenic myxoma of the maxilla: surgical management and case report

What is the future for General Surgery in Model 3 Hospitals?

Fumaric acid esters for psoriasis: a systematic review

Re: Re: Cross-sectional audit on the relevance of Elevated National Early Warning Score in medical patients at a Model 2 hospital in Ireland

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Sind Betablocker auch für ältere herzschwache Personen nützlich?

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

Manche Gestagene können das Risiko für Meningeome erhöhen

Stillende Frauen haben geringeres kardiovaskuläres Risiko

Update Innere Medizin